PolyPid (NASDAQ:PYPD – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $13.00 target price on the stock. HC Wainwright‘s price objective would indicate a potential upside of 96.97% from the company’s previous close.
Other equities research analysts also recently issued reports about the company. Craig Hallum set a $12.00 target price on PolyPid in a research report on Wednesday, July 22nd. Oppenheimer began coverage on PolyPid in a report on Tuesday, October 27th. They issued an “outperform” rating and a $10.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of PolyPid in a research report on Friday, September 18th. Finally, Wall Street Zen upgraded PolyPid from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, PolyPid currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.
View Our Latest Report on PolyPid
PolyPid Price Performance
PolyPid stock opened at $6.60 on Thursday. PolyPid has a fifty-two week low of $3.50 and a fifty-two week high of $7.15. The firm has a fifty day moving average price of $5.32 and a two-hundred day moving average price of $4.78. The firm has a market cap of $125.95 million, a price-to-earnings ratio of -4.46 and a beta of 1.43.
PolyPid (NASDAQ:PYPD – Get Free Report) last issued its quarterly earnings results on Wednesday, November 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.91 by ($1.15). The firm had revenue of $30.00 million during the quarter, compared to the consensus estimate of $30.00 million. As a group, sell-side analysts expect that PolyPid will post -0.44 earnings per share for the current year.
Hedge Funds Weigh In On PolyPid
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. HighTower Advisors LLC lifted its holdings in shares of PolyPid by 18.2% during the 3rd quarter. HighTower Advisors LLC now owns 13,000 shares of the company’s stock worth $69,000 after acquiring an additional 2,000 shares during the period. B. Riley Wealth Advisors Inc. increased its stake in PolyPid by 32.7% in the third quarter. B. Riley Wealth Advisors Inc. now owns 20,085 shares of the company’s stock valued at $106,000 after acquiring an additional 4,955 shares during the period. AXQ Capital LP bought a new stake in PolyPid in the second quarter valued at about $87,000. Renaissance Technologies LLC acquired a new position in PolyPid in the first quarter worth about $81,000. Finally, Connective Capital Management LLC acquired a new position in PolyPid in the second quarter worth about $343,000. 26.47% of the stock is owned by institutional investors.
PolyPid Company Profile
PolyPid Ltd. (NASDAQ: PYPD) is a clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to provide controlled and sustained drug release at treatment sites. The company’s technology is intended to maintain therapeutic drug concentrations over extended periods while limiting systemic exposure. PolyPid’s lead product candidate is D-PLEX100, an investigational formulation based on doxycycline and the company’s proprietary PLEX polymeric matrix. It is being developed for the prevention of surgical-site infections, initially in patients undergoing colorectal surgery.
Featured Stories
- Five stocks we like better than PolyPid
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
